Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.

被引：4
|
作者：
Piha-Paul, Sarina Anne
Sachdev, Jasgit C.
Barve, Minal A.
LoRusso, Patricia
Szmulewitz, Russell Zelig
Patel, Sapna Pradyuman
McKee, Mark D.
Wolff, Johannes E.
Hu, Beibei
Sood, Anjla
Chen, Xiaotian
Wilson, Sarah C.
O'Neil, Bert H.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] HonorHealth Res Inst TGen, Scottsdale, AZ USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] AbbVie Inc, N Chicago, IL USA
[7] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2510
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors.
    Xu, Rui-hua
    Qiu, Miao-Zhen
    Zhang, Yang
    Wei, Xiao-Li
    Hu, Chaohong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
    Qin, Angel
    Kalemkerian, Gregory Peter
    Mohindra, Nisha Anjali
    Patel, Jyoti D.
    Karapetis, Christos Stelios
    Carlisle, Jennifer W.
    Sands, Jacob
    Spira, Alexander I.
    Gao, Bo
    Amin, Harshad
    Paudyal, Bishnuhari
    Frank, Genevieve
    Sun, Xuemei
    Xu, Yang
    Wang, Cunlin
    Fu, Tommy
    Winkler, Robert
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
    LoRusso, Patricia
    Rasco, Drew W.
    Shapiro, Geoffrey
    Mita, Alain C.
    Azad, Nilofer Saba
    Swiecicki, Paul
    El-Khoueiry, Anthony B.
    Gandara, David R.
    Kummar, Shivaani
    Tanajian, Hovig
    Taylor, Jaruwan
    Bottone, Frank G.
    Toguchi, Marchi
    Hindley, Chris
    Chan, Danna
    Oganesian, Aram
    Keer, Harold N.
    Dao, Kim-Hien T.
    Sullivan, Ryan J.
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
    LoRusso, Patricia
    Rasco, Drew
    Shapiro, Geoffrey
    Janku, Filip
    Mita, Alain
    Azad, Nilofer
    Toguchi, Marcia
    Hindley, Chris
    Bradley, Shannon
    Chan, Danna
    Keer, Harold
    Dao, Kim-Hien
    Sullivan, Ryan J.
    Spira, Alexander
    CANCER RESEARCH, 2021, 81 (13)
  • [25] First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma
    Middleton, M.
    Rasco, D. W.
    Olszanski, A. J.
    Corrie, P.
    Lorigan, P.
    Plummer, R.
    Larkin, J.
    Pavlick, A.
    Zhou, X.
    Yuan, Z.
    Gangolli, E.
    Kneissl, M.
    Bozon, V.
    Gonzalez, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 117 - 117
  • [26] First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.
    Robbrecht, Debbie
    Eskens, Ferry
    Calvo, Emiliano
    He, Xiaomin
    Hirai, Hiroshi
    Soni, Nital
    Cook, Natalie
    Dowlati, Afshin
    Fasolo, Angelica
    Moreno, Victor
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
    Yk, Wang
    Gong, Jifang
    Sun, Yuping
    Zhang, Jian
    Ni, Shuqin
    Hou, Jie
    Chen, Xiaohua
    Wang, Yusheng
    Yu, Qin
    Qu, Xiangdong
    Du, Yejie
    Wei, Li
    Yu, Tao
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 382 - 382
  • [28] First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban Akmal
    Chen, Zi
    Huang, Bo
    Konopleva, Marina
    Brander, Danielle M.
    Rizzieri, David
    Lasica, Masa
    Tam, Constantine Si Lun
    Yannakou, Costas K.
    Prince, H. Miles
    Davids, Matthew Steven
    He, Zhicong
    Lu, Ming
    Ahmad, Mohammad
    Li, Mingyu
    Liang, Zhiyan
    Mudenda, Boyd
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A first-in-human study of AMG 780, an angiopoietin-1 and-2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors.
    Dowlati, Afshin
    Vlahovic, Gordana
    Natale, Ronald B.
    Rasmussen, Erik
    Singh, Indrajeet
    Hwang, Yuying C.
    Rossi, John
    Bass, Michael
    Friberg, Gregory R.
    Pickett-Gies, Cheryl Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
    Berlin, J.
    Keedy, V. L.
    Janne, P. A.
    Yee, L.
    Rizvi, N. A.
    Jin, X.
    Copigneaux, C.
    Hettmann, T.
    Beaupre, D. M.
    LoRusso, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345